US Capital Global Provides $8 Million Financing for Pioneering MedTech Company

San Francisco-based private financial group structures and puts in place non-dilutive financing to help MedTech firm bring to market pioneering, patented DNA biomarker technology.

SAN FRANCISCO, AUGUST 2019 – US Capital Global has provided $8 million in debt financing for a medical disease-testing kit company based in the Southeastern United States. Headquartered in San Francisco, US Capital Global provides sophisticated debt, equity, and investment products to lower middle market companies and investors.

This expanding MedTech company aims to deliver earlier and more accurate testing for serious health conditions and diseases, such as prostate cancer, using pioneering, patented mitochondrial DNA biomarker technology. The firm sought growth capital and working capital to develop and bring to market its non-invasive disease-testing products.

“We are very pleased to have provided $8 million in debt financing for this MedTech firm,” said Jeffrey Sweeney, Chairman and CEO at US Capital Global. “As an early-stage company developing a portfolio of innovative and highly promising patent-protected products, the firm approached US Capital Global for a non-dilutive capital infusion of at least $5 million. US Capital Global was able to provide the firm with $8 million in customized debt financing, greatly exceeding the company’s expectations.”

About the Company

Based in the Southeastern United States, this MedTech company aims to deliver earlier and more accurate testing of illnesses that are difficult to diagnose using its own pioneering, patented technology. The company’s technology uses mitochondrial DNA to identify biomarkers for the recognition of disease in humans, with the aim of reducing unnecessary invasive surgery, uncertainty, and deaths for patients across the world.

About US Capital Global

Established in 1998, US Capital Global leverages the latest FinTech and RegTech innovation to provide sophisticated debt, equity, and investment products to lower middle market companies and investors. The US Capital Global group manages direct investment funds and provides wealth management and capital raise services. Operating with its registered investment bank affiliate, US Capital Global Securities, LLC, the firm acts as a licensed placement agent for companies, funds, and projects, and collaborates closely with its peers in professional banking and investment advisory. www.uscapglobal.com

To learn more about US Capital Global, email Jeffrey Sweeney, Chairman and CEO, at jsweeney@uscapglobal.comor call +1 415-889-1010.

Jeff Sweeney